PHARMACOKINETICS AND METABOLISM OF ANTIEPILEPTIC DRUGS IN ELDERLY PATIENTS

该子项目是利用NIH/NCRR资助的中心赠款提供的资源的许多研究子项目之一。子项目和研究者（PI）可能从另一个NIH来源获得主要资金，因此可以在其他CRISP条目中表示。所列机构为中心机构，不一定为研究者机构。我们的目标是研究高龄对抗癫痫药物的药代动力学和代谢的影响。将对选定的老年和成年男性和女性非卧床患者使用苯妥英（PHT或CBZ）作为癫痫单药治疗进行评价。患者将接受一部分口服剂量的PHT，作为稳定标记的PHT，在5分钟内静脉内给予100 mg（仅一次）。稳定标记的PHT不具有放射性，并表现出与未标记PHT相同的动力学和代谢。将分析血液样本和尿液样本。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Our goal is to investigate the effect of advanced age on antiepileptic drug pharmacokinetics and metabolism. Selected elderly and adult male and female ambulant patients taking phenytoin (PHT or CBZ) as monotherapy for epilepsy will be evaluated. The patients will receive a portion of their oral dose of PHT as stable-labeled PHT given intravenously as 100 mg over 5 minutes (one time only). Stable-labeled PHT is NOT radioactive and exhibits the same kinetics and metabolism as unlabeled PHT. Blood samples and urine collections will be analyzed.